1 |
ICV203 |
27.99 | 68.79% | 40.69% |
virus: 3C-like protease | P0DTD1 | SARS 3CL(IC50=41.39µM) |
2 |
ICV18 |
26.85 | 61.82% | 43.43% |
virus: 3C-like protease | P0DTD1 | SARS 3CL(IC50=43µM) |
3 |
ICV201 |
25.63 | 68.24% | 37.56% |
virus: 3C-like protease | P0DTD1 | SARS 3CL(IC50=77.09µM) |
4 |
ICV429 |
24.9 | 69.45% | 35.85% |
human: Histamine H1 receptor | P35367 | MERS-CoV(IC50=14.4µM) |
5 |
ICV16 |
24.7 | 76.01% | 32.5% |
virus: 3C-like protease | P0DTD1 | SARS 3CL(IC50=30µM) |
6 |
ICV413 |
24.29 | 60.88% | 39.91% |
human: Calcium channel | NA | MERS(IC=4.07µM) Vero |
7 |
ICV327 |
23.71 | 70.71% | 33.54% |
virus: Papain-like protease | P0DTD1 | SARS PL(IC50=18µM) |
8 |
ICV200 |
23.43 | 71.57% | 32.73% |
virus: 3C-like protease | P0DTD1 | SARS 3CL(IC50=101.38µM) |
9 |
ICV89 |
23.39 | 64.9% | 36.04% |
virus: 3C-like protease | P0DTD1 | SARS 3CL(IC50=2µM) |
10 |
ICV57 |
22.38 | 64.31% | 34.8% |
virus: 3C-like protease | P0DTD1 | SARS 3CL(IC50=1µM); SARS(ec50=0.18µM) Vero E6 |
11 |
ICV73 |
22.22 | 65.21% | 34.08% |
virus: 3C-like protease | P0DTD1 | Replicon (BHK) (IC50=2µM); SARS(IC50=8.9µM) Vero |
12 |
ICV412 |
22.11 | 61.8% | 35.78% |
human: Calcium channel | NA | MERS(IC=2.36µM) Vero |
13 |
ICV17 |
21.84 | 73.12% | 29.86% |
virus: 3C-like protease | P0DTD1 | SARS 3CL(IC50=65µM) |
14 |
ICV328 |
21.45 | 63.96% | 33.54% |
virus: Papain-like protease | P0DTD1 | SARS PL(IC50=1.9µM) |
15 |
ICV88 |
21.4 | 62.61% | 34.18% |
virus: 3C-like protease | P0DTD1 | SARS 3CL(IC50=0.06µM) |
16 |
ICV186 |
21.33 | 57.36% | 37.18% |
virus: 3C-like protease | P0DTD1 | SARS 3CL(IC50=38.57µM) |
17 |
ICV56 |
21.04 | 53.94% | 39% |
virus: 3C-like protease | P0DTD1 | SARS 3CL(IC50=5µM); SARS(ec50=9.45µM) Vero E6 |
18 |
ICV130 |
20.98 | 65.27% | 32.14% |
virus: 3C-like protease | P0DTD1 | SARS 3CL(Ki=35.3µM) |
19 |
ICV92 |
20.45 | 63.2% | 32.35% |
virus: 3C-like protease | P0DTD1 | SARS 3CL(IC50=4µM) |
20 |
ICV58 |
20.42 | 67.15% | 30.41% |
virus: 3C-like protease | P0DTD1 | SARS 3CL(IC50=10µM); SARS(ec50=0.11µM) Vero E6 |